The results from the renal cell carcinoma (RCC) group of patients in a phase 1b/2 trial of a combination of lenvatinib plus pembrolizumab were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week.

In this study, 30 patients with metastatic clear cell RCC were treated with oral lenvatinib daily plus intravenous pembrolizumab every 3 weeks.  Objective response rate at 24 weeks was 63.3% and median progression-free survival was 17.7 months. The most common adverse events were diarrhoea, fatigue, hypothyroidism, sore mouth, and nausea.

The combination of lenvatinib plus pembrolizumab showed promising anti-tumour activity with manageable side effects. A phase 3 trial of lenvatinib plus pembrolizumab and lenvatinib plus everolimus versus sunitinib for the first-line treatment of advanced RCC is underway.

Read the ASCO abstract here